http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lu Miao-Hua,Lin Dong-Qiang,Wu Yuan-Chun,Yun Jun-Xian,Mei Le-He,Yao Shan-Jing The Korean Society for Biotechnology and Bioengine 2005 Biotechnology and Bioprocess Engineering Vol.10 No.2
Mixed-mode hydrophobic/ionic matrices exhibit a salt-tolerant property for adsorbing target protein from high-ionic strength feedstock, which allows the application of undiluted feedstock via an expanded bed process. In the present work, a new type of mixed-mode adsorbent designed for expanded bed adsorption, Fastline $PRO^{\circledR}$, was challenged for the capture of nattokinase from the high ionic fermentation broth of Bacillus subtilis. Two important factors, pH and ion concentration, were investigated with regard to the performance of nattokinase ad-sorption. Under initial fermentation broth conditions (pH 6.6 and conductivity of 10 mS/cm) the adsorption capacity of nattokinase with Fastline PRO was high, with a maximum capacity of 5,350 U/mL adsorbent. The elution behaviors were investigated using packed bed adsorption experiments, which demonstrated that the effective desorption of nattokinase could be achieved by effecting a pH of 9.5. The biomass pulse response experiments were carried out in order to evaluate the biomass/adsorbent interactions between Bacillus subtilis cells and Fastline PRO, and to demonstrate a stable expanded bed in the feedstock containing Bacillus subtilis cells. Finally, an EBA process, utilizing mixed-mode Fastline PRO adsorbent, was optimized to capture nattokinase directly from the fermentation broth. The purification factor reached 12.3, thereby demonstrating the advantages of the mixed-mode EBA in enzyme separation.
Lu, Yue,Zhang, Yan-Yan,Hu, Ying-Chun,Lu, Yan-Hua 대한약학회 2014 Archives of Pharmacal Research Vol.37 No.9
2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC) is a chalcone isolated from the buds of Cleistocalyx operculatus (Roxb.) Merr. et Perry, and the hepatoprotective effects of DMC on Kunming mice have been studied in previous study. However, the effects of DMC on hepatocyte toxicity and corresponding mechanism remain unclear. The aim of this study was to evaluate the hepatoprotective mechanism of DMC in human hepatocytes (L02) treated with $H_2O_2$. The results demonstrated that pretreatment with DMC effectively protected $H_2O_2$-induced cell viability loss, cell membrane damage (lactate dehydrogenase, nitric oxide production and caspase-3 accumulation. Besides, DMC pretreatment increased the amount of glutathione, decreased malondialdehyde and the percentage of apoptotic L02 cells compared with only $H_2O_2$ treated group. Taken together, these results indicated that DMC had hepatoprotective effects against $H_2O_2$-induced liver injury by alleviating oxidative stress and apoptosis process in L02 cells, and DMC might be a potential candidate for the intervention of liver diseases.
Tazarotene-Induced Gene 1 Interacts with DNAJC8 and Regulates Glycolysis in Cervical Cancer Cells
Chun-Hua Wang,Rong-Yaun Shyu,Chang-Chieh Wu,Mao-Liang Chen,Ming-Cheng Lee,Yi-Yin Lin,Lu-Kai Wang,Shun-Yuan Jiang,Fu-Ming Tsai 한국분자세포생물학회 2018 Molecules and cells Vol.41 No.6
The tazarotene-induced gene 1 (TIG1) protein is a retinoid-inducible growth regulator and is considered a tumor suppressor. Here, we show that DnaJ heat shock protein family member C8 (DNAJC8) is a TIG1 target that regulates glycolysis. Ectopic DNAJC8 expression induced the translocation of pyruvate kinase M2 (PKM2) into the nucleus, subsequently inducing glucose transporter 1 (GLUT1) expression to promote glucose uptake. Silencing either DNAJC8 or PKM2 alleviated the upregulation of GLUT1 expression and glucose uptake induced by ectopic DNAJC8 expression. TIG1 interacted with DNAJC8 in the cytosol, and this interaction completely blocked DNAJC8-mediated PKM2 translocation and inhibited glucose uptake. Furthermore, increased glycose uptake was observed in cells in which TIG1 was silenced. In conclusion, TIG1 acts as a pivotal repressor of DNAJC8 to enhance glucose uptake by partially regulating PKM2 translocation.
Chun Li,Zhi-Jun Wuxiao,Xiaoqin Chen,Guanjun Chen,Yue Lu,Zhongjun Xia,Yang Liang,Hua Wang 대한암학회 2020 Cancer Research and Treatment Vol.52 No.2
Purpose Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined. Materials and Methods To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berlin–Frankfurt–Mu!nster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. This retrospective study consecutively enrolled 207 adult LBL patients at two hospitals from 2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors. Results In the present study, most clinical characteristics were similar between the two treatment groups except for age and lactate dehydrogenase (LDH) level. Patients treated with modified NHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHLBFM- 95 regimen produced better treatment outcomes than those with HyperCVAD/MA in patients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high Eastern Cooperative Oncology Group scores, and bone marrow involvement were independent risk factors in T-LBL. No patients interrupted treatment for severe adverse events. Conclusion The results suggested that the modified regimen is well-tolerated and can produce the promising outcomes in patients with T-LBL or patients < 40 years.
( Li Chun Wang ),( En Qiang Chen ),( Xiao Feng Zhu ),( Zhong Hua Xiong ),( Li Liu ),( Lu Xu ),( Xue Zhong Lei ),( Cong Liu ),( Hong Tang ) 대한간학회 2011 Gut and Liver Vol.5 No.4
Background/Aims: To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV. Methods: In total, 168 treatment-naive CHB patients were enrolled, including 117 hepatitis B e antigen (HBeAg)-positive patients and 51 HBeAg-negative patients who met the inclusion criteria. All patients were treated with ADV 10 mg per day for 48 weeks. Multiple logistic regression analyses were used to investigate baseline factors, and responses at weeks 12 and 24 were analyzed as predictive values. Results: Multiple regression analyses showed that baseline HBeAg status and HBV DNA levels signifi cantly affected the virological response (VR) (p<0.05), baseline ALT levels were an independent predictor of serological response (SR) (p<0.05) and the body mass index (BMI) may affect the biochemical response (BR) (p<0.05). There was a statistically significant difference in the VR and SR between patients with a primary nonresponse (PNR) at week 12 and those with a VR at week 12 (p<0.01). Additionally, the VR was significantly different between patients with HBV DNA lower than 103 copies/mL at week 24 and those with greater than 103 copies/mL (p<0.01). Conclusions: Patients with negative HBeAg, lower HBV DNA levels and higher ALT values at baseline are more suitable for ADV treatment, whereas patients with lower BMIs may be more amenable to ALT normalization. Adjustments for treatment strategy should be considered if PNR at week 12 or HBV DNA ≥103 copies/mL at week 24 is observed. (Gut Liver 2011;5:478-485)
Yue Lu,Yan-Yan Zhang,Ying-Chun Hu,Yan-Hua Lu 대한약학회 2014 Archives of Pharmacal Research Vol.37 No.9
2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone(DMC) is a chalcone isolated from the buds of Cleistocalyxoperculatus (Roxb.) Merr. et Perry, and thehepatoprotective effects of DMC on Kunming mice havebeen studied in previous study. However, the effects ofDMC on hepatocyte toxicity and corresponding mechanismremain unclear. The aim of this study was to evaluate thehepatoprotective mechanism of DMC in human hepatocytes(L02) treated with H2O2. The results demonstrated thatpretreatment with DMC effectively protected H2O2-inducedcell viability loss, cell membrane damage (lactate dehydrogenase,nitric oxide production and caspase-3 accumulation. Besides, DMC pretreatment increased the amount ofglutathione, decreased malondialdehyde and the percentageof apoptotic L02 cells compared with only H2O2 treatedgroup. Taken together, these results indicated that DMC hadhepatoprotective effects against H2O2-induced liver injuryby alleviating oxidative stress and apoptosis process in L02cells, and DMC might be a potential candidate for theintervention of liver diseases.
Tazarotene-Induced Gene 1 Interacts with DNAJC8 and Regulates Glycolysis in Cervical Cancer Cells
Wang, Chun-Hua,Shyu, Rong-Yaun,Wu, Chang-Chieh,Chen, Mao-Liang,Lee, Ming-Cheng,Lin, Yi-Yin,Wang, Lu-Kai,Jiang, Shun-Yuan,Tsai, Fu-Ming Korean Society for Molecular and Cellular Biology 2018 Molecules and cells Vol.41 No.6
The tazarotene-induced gene 1 (TIG1) protein is a retinoidinducible growth regulator and is considered a tumor suppressor. Here, we show that DnaJ heat shock protein family member C8 (DNAJC8) is a TIG1 target that regulates glycolysis. Ectopic DNAJC8 expression induced the translocation of pyruvate kinase M2 (PKM2) into the nucleus, subsequently inducing glucose transporter 1 (GLUT1) expression to promote glucose uptake. Silencing either DNAJC8 or PKM2 alleviated the upregulation of GLUT1 expression and glucose uptake induced by ectopic DNAJC8 expression. TIG1 interacted with DNAJC8 in the cytosol, and this interaction completely blocked DNAJC8-mediated PKM2 translocation and inhibited glucose uptake. Furthermore, increased glycose uptake was observed in cells in which TIG1 was silenced. In conclusion, TIG1 acts as a pivotal repressor of DNAJC8 to enhance glucose uptake by partially regulating PKM2 translocation.
Li-Chun Wang,En-Qiang Chen,Xiao-Feng Zhu,Zhong-Hua Xiong,Li Liu,Lu Xu,Xue-Zhong Lei,Cong Liu,Hong Tang 거트앤리버 소화기연관학회협의회 2011 Gut and Liver Vol.5 No.4
Background/Aims: To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV. Methods:In total, 168 treatment-naïve CHB patients were enrolled,including 117 hepatitis B e antigen (HBeAg)-positive patients and 51 HBeAg-negative patients who met the inclusion criteria. All patients were treated with ADV 10 mg per day for 48 weeks. Multiple logistic regression analyses were used to investigate baseline factors, and responses at weeks 12and 24 were analyzed as predictive values. Results: Multiple regression analyses showed that baseline HBeAg status and HBV DNA levels signifi cantly affected the virological response (VR) (p<0.05), baseline ALT levels were an independent predictor of serological response (SR) (p<0.05) and the body mass index (BMI) may affect the biochemical response (BR)(p<0.05). There was a statistically significant difference in the VR and SR between patients with a primary nonresponse (PNR) at week 12 and those with a VR at week 12 (p<0.01). Additionally, the VR was significantly different between patients with HBV DNA lower than 10^3 copies/mL at week 24 and those with greater than 10^3 copies/mL (p<0.01). Conclusions: Patients with negative HBeAg, lower HBV DNA levels and higher ALT values at baseline are more suitable for ADV treatment, whereas patients with lower BMIs may be more amenable to ALT normalization. Adjustments for treatment strategy should be considered if PNR at week 12 or HBV DNA ≥103 copies/mL at week 24 is observed.